Effect of pcsk9 antibodies on neurocognitive outcomes and improved survival in patients at higher risk: a meta-analysis of randomised controlled trials
Event: ESC Congress 2016
Topic: Drug therapy
Session: Lipid-lowering agents - New perspectives
ESC 365 is supported by
